- Company
- “RSA expansion, a foundation to expedite new drug listing"
- by Eo, Yun-Ho Jan 10, 2020 06:26am
- A ‘new drug’ holds the foremost value of the pharmaceutical industry. And global pharmaceutical companies’ eyes are currently fixated on the ‘adequate value of new drug’ than ever before. As the era of high-cost drug has come, government and pharmaceutical industry’s gap in views of drug pricing has never been so apart. Korea Research-
- Policy
- Choline alfoscerates, 82 generics were approved last year
- by Lee, Tak-Sun Jan 10, 2020 06:26am
- Despite the controversy over last year's efficacy, choline alfoscerate formulations were found to have received 82 new licenses last year. Only 267 cumulative licensed items are available. On the 9th of last year, an investigation into the approved items of the same ingredient was conducted through MFDS' website. The choline alfoscerate
- Company
- The controversy of Eliquis' fluctuating price
- by Jung, Hye-Jin Jan 10, 2020 06:25am
- The price of Eliquis, an anticoagulant drug, Apixaban, has fluctuated several times. Wholesalers and pharmacies dealing with dispensing and distribution are also confused. In particular, as the most recent provisional disposal application that Korea BMS applied for was accepted earlier than expected, some pharmacies and wholesalers had to
- Policy
- 23 new drugs approved last year with no Korean-made
- by Lee, Tak-Sun Jan 10, 2020 06:25am
- Apparently, total 23 investigational new drugs have been approved in Korea last year. Compared to 2018, the number was increased by 14 but not one of them was made in Korea. Moreover, two incrementally modified drugs (IMDs) and three biosimilars have been cleared. According to Ministry of Food and Drug Safety (MFDS)’s pharmaceutical inf
- Policy
- Ibrutinib's Asian Standard Therapy Strategy Revealed
- by Lee, Jeong-Hwan Jan 10, 2020 06:24am
- A domestic study shows that allogeneic hematopoietic stem cell transplantation is the ultimate treatment strategy for patients who do not have treatment effect after 3 months after taking Imbruvica (Ibrutinib/Janssen), a kind of hematologic cancer. The researchers also found that the initial prognostic factors of mantle cell lymphoma and t
- Company
- Valsartan's third payment deadline has expired
- by Chon, Seung-Hyun Jan 10, 2020 06:24am
- The third payment deadline for the Valsartan damages claim urged by health authorities has ended. Most of the companies that did not pay the compensation were refused to pay. The health authorities say they will continue to incentivize payments, but a lawsuit filed by pharmaceutical companies will conclude the legitimacy of government action.
- Company
- PPC signs co-marketing partnership with Biosuntek
- by Eo, Yun-Ho Jan 10, 2020 06:23am
- PPC Korea and Biosuntek Laboratory (“Biosuntek”) have agreed to co-market pharmaceutical clinical development. PPC Korea, a contract research organization (CRO) providing service in Asian region, has invested in a bioequivalence test analyst institute, Biosuntek Laboratory and signed a strategic partnership agreement on Jan. 8. The
- Company
- Big Pharmas butting heads over Faslodex combination
- by Eo, Yun-Ho Jan 9, 2020 09:06am
- Three investigational drugs are busy preparing for applying reimbursement on a combination therapy with Faslodex. The competing three investigational drugs are cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor treatment&8212;Pfzier’s Ibrance (palbociclib), Lilly’s Verzenio (abemaciclib), and Novartis’ Kisqali (ribociclib). The
- Policy
- Exclusive rights such as Betmiga and Olosta expire
- by Lee, Tak-Sun Jan 9, 2020 06:43am
- In 2020, the generics market is likely to be generally calm, with a small number of large-scale items whose exclusive rights expire. Nevertheless,the exclusive right of blockbuster products like hypersensitivity bladder treatment ‘Betmiga’ (Mirabegron/Astellas), hypertension-hyperlipidemia treatment ‘Duowell’(Telmisartan, Rosuvastatin/
- Policy
- The MSI invests ₩420 billion to bio-based technologies
- by Lee, Jeong-Hwan Jan 9, 2020 06:42am
- The government will invest &8361;420 billion to foster bio as a next-generation growth industry and invests &8361;61.4 billion in finding and verifying new drugs. The budget increased by 10.1% compared to the previous year for the development of bio-based technologies. New drugs, medical devices, brain research, and bio-big data are the are
